Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2. Nature, 2023; DOI: 10.1038/s41586-023-06727-9 ...

“VMAT2 is a small membrane protein,” explained co-first author Yaxin Dai, PhD, at St. Jude department of structural biology. “This makes it a very challenging target for cryo-EM structure ...

“VMAT2 is a small membrane protein,” explained co-first author Yaxin Dai, PhD., St. Jude Department of Structural Biology. “This makes it a very challenging target for cryo-EM structure ...

Researchers recently found that the pharmacokinetic properties of vesicular monoamine transporter 2 inhibitors may play a role in the treatment of tardive dyskinesia. Healio Neurology spoke with ...

Neurocrine Biosciences has commenced the Phase I clinical trial of its oral, small molecule vesicular monoamine transporter 2 (VMAT2) inhibitor, NBI-1140675 in healthy adults. The trial aims to ...

- Novel once-weekly injectable VMAT2 inhibitor targets underserved patients with serious adherence and access challenges – - Potential expansion into Huntington’s chorea – an underserved ...

VMAT2 controls the amount of dopamine in beta-cells thereby protecting pancreatic beta-cells from excessive oxidative stress. Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy ...

Learn about vesicular monoamine transporter 2 (VMAT2) inhibitors, a medication used to manage chorea, or uncontrolled movements, in Huntington’s disease.